WHO: nearly 5,000 H1N1 flu deaths worldwide

Slides
Photos

(Agencies)
Updated: 2009-10-24 03:43

GENEVA: Nearly 5,000 people have reportedly died from H1N1 flu since it emerged this year and developed into a global epidemic, the World Health Organization said Friday.

Since most countries have stopped counting individual H1N1 flu cases, the figure is considered an underestimate.

WHO: nearly 5,000 H1N1 flu deaths worldwide
Carol Lagoni checks her arm after receiving an H1N1 flu shot Friday Oct. 23, 2009 in Culver City, Calif. [Agencies]

WHO said there were 4,999 total deaths through Oct. 18, most of them in the Western Hemisphere. The figure was up 264 from a week earlier.

Iceland had its first H1N1 flu death this week, and WHO said Sudan and Trinidad and Tobago also reported deaths from the virus for the first time this week.

In the United States, H1N1 flu caused at least 95 children's deaths since April, the Centers for Disease Control and Prevention said Friday.

Forty-six states now have widespread flu activity, the CDC said, adding that only Connecticut, Hawaii, New Jersey and South Carolina are without widespread flu.

In London, drug maker GlaxoSmithKline PLC said children may only need one shot of its H1N1 flu vaccine to be protected.

In its statement Friday, Glaxo said one dose was enough to boost children's immune systems to fight the virus, based on data from a trial in Spain in 200 children aged six months to 3 years.

Glaxo's finding comes after experts said they expected children would need two doses, since their immune systems are weaker than those of adults. Last week, rival vaccine maker Sanofi Aventis said children would likely need two doses of vaccine against H1N1 flu.

GlaxoSmithKline's Pandemrix vaccine contains an adjuvant, a chemical compound that stretches a vaccine's active ingredient and increases the human body's immune response. While European flu vaccines commonly use adjuvants, there is limited data on how safe they are in groups including children and pregnant women.

The adjuvant in Glaxo's H1N1 flu vaccine has been used in more than 41,000 people in bird flu, H1N1 flu and regular flu vaccines.

H1N1 flu vaccines in the US do not have adjuvants. Some countries have ordered special stocks of vaccines without adjuvants for their at-risk populations.

While most people recover from H1N1 flu without needing medical treatment, the virus strikes children particularly hard.

According to data from the US Centers for Disease Control and Prevention, more than half of hospitalizations and nearly a quarter of deaths due to H1N1 flu are in children and adults under 25.

An Associated Press-GfK poll found that a third of American parents don't want their children to get the H1N1 flu shot, with many citing concerns about side effects.

Of the thousands of people who have so far received the H1N1 flu vaccine, the most commonly reported side effects have been soreness where the injection was given and minor flu symptoms.